Find Ruxolitinib Phosphate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1092939-17-7, Jakafi, (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate, Jakavi, Ruxolitinib (phosphate), Ruxolitinib monophosphate
Molecular Formula
C17H21N6O4P
Molecular Weight
404.4  g/mol
InChI Key
JFMWPOCYMYGEDM-XFULWGLBSA-N
FDA UNII
436LRU32H5

Ruxolitinib Phosphate
Ruxolitinib Phosphate is the phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.
1 2D Structure

Ruxolitinib Phosphate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;phosphoric acid
2.1.2 InChI
InChI=1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1
2.1.3 InChI Key
JFMWPOCYMYGEDM-XFULWGLBSA-N
2.1.4 Canonical SMILES
C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O
2.1.5 Isomeric SMILES
C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O
2.2 Other Identifiers
2.2.1 UNII
436LRU32H5
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 3r)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile

2. Inc-424

3. Inc424

4. Inca24

5. Incb-018424

6. Incb-018424 Phosphate

7. Incb-018424 Salt

8. Incb-18424

9. Incb-18424 Phosphate

10. Incb018424

11. Incb018424 Phosphate

12. Jakafi

13. Jakavi

14. Opzelura

15. Ruxolitinib

16. Ruxolitinib (as Phosphate)

17. Ruxolitinib Monophosphate

2.3.2 Depositor-Supplied Synonyms

1. 1092939-17-7

2. Jakafi

3. (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile Phosphate

4. Jakavi

5. Ruxolitinib (phosphate)

6. Ruxolitinib Monophosphate

7. Incb018424 Phosphate

8. Ruxolitinib (as Phosphate)

9. Incb-018424 Phosphate

10. Incb-018424 Salt

11. Ruxolitinib Phosphate [usan]

12. Incb-18424 Phosphate

13. Incb018424 Salt

14. Chebi:66917

15. 436lru32h5

16. 1092939-17-7 (phosphate)

17. (betar)-beta-cyclopentyl-4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazole-1-propanenitrile Phosphate

18. Incb-18424

19. Ruxolitinib Phosphate Salt

20. (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]propanenitrile Phosphate

21. (3r)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)propanenitrile Phosphate (1:1)

22. Phosphenoperoxoic Acid Compound With (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)- 1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile And Dihydrogen (1:1:1)

23. Opzelura

24. Unii-436lru32h5

25. (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]propanenitrilephosphoricacid

26. Jakafi (tn)

27. Jakavi (tn)

28. Ruxolitinib Phosphate(incb018424)

29. Inc 424 Phosphate

30. Incb 018424 Phosphate

31. Incb-424

32. Schembl1369365

33. Chembl1795071

34. Amy5620

35. Dtxsid00911086

36. Ruxolitinib Phosphate (jan/usan)

37. Ruxolitinib Phosphate [mi]

38. Ruxolitinib Phosphate [jan]

39. Ex-a2660

40. Cs1956

41. Mfcd18452860

42. S5243

43. Akos024464417

44. Ruxolitinib (incb-18424) Phosphate

45. Ruxolitinib Phosphate [who-dd]

46. Bcp9000783

47. Ccg-268687

48. Cs-0326

49. 1h-pyrazole-1-propanenitrile, Beta-cyclopentyl-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-,(betar)-, Phosphate (1:1)

50. Ac-30901

51. As-74723

52. Hy-50858

53. Ruxolitinib Phosphate [orange Book]

54. Ruxolitinib (as Phosphate) [ema Epar]

55. D09960

56. J-501793

57. Q27135517

58. (3r)-3-cyclopentyl-3-(4-{7h-pyrrolo[2,3-d]pyrimidin-4-yl}-1h-pyrazol-1-yl)propanenitrile; Phosphoric Acid

59. (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;phosphoric Acid

60. (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrilephosphate

61. 1h-pyrazole-1-propanenitrile,.beta.-cyclopentyl-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-,(.beta.r)-,phosphate (1:1)

62. Phosphoric Acid--3-cyclopentyl-3-[4-(1h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]propanenitrile (1/1)

2.4 Create Date
2009-01-19
3 Chemical and Physical Properties
Molecular Weight 404.4 g/mol
Molecular Formula C17H21N6O4P
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count8
Rotatable Bond Count4
Exact Mass404.13619017 g/mol
Monoisotopic Mass404.13619017 g/mol
Topological Polar Surface Area161 Ų
Heavy Atom Count28
Formal Charge0
Complexity503
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameJakafi
PubMed HealthRuxolitinib (By mouth)
Drug ClassesAntineoplastic Agent
Active IngredientRuxolitinib phosphate
Dosage FormTablet
RouteOral
Strengtheq 5mg base; eq 20mg base; eq 15mg base; eq 10mg base; eq 25mg base
Market StatusPrescription
CompanyIncyte

2 of 2  
Drug NameJakafi
PubMed HealthRuxolitinib (By mouth)
Drug ClassesAntineoplastic Agent
Active IngredientRuxolitinib phosphate
Dosage FormTablet
RouteOral
Strengtheq 5mg base; eq 20mg base; eq 15mg base; eq 10mg base; eq 25mg base
Market StatusPrescription
CompanyIncyte

4.2 Drug Indication

* Myelofibrosis (MF):

Jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

* Polycythaemia vera (PV):

Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.

* Graft versus host disease (GvHD):

Jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5. 1).


Treatment of chronic Graft versus Host Disease (cGvHD)


Treatment of acute graft-versus-host disease (aGvHD)


Treatment of vitiligo


5 Pharmacology and Biochemistry
5.1 ATC Code

L01EJ01


API SUPPLIERS

read-more
read-more

01

Biophore India Pharmaceuticals Pvt...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Biophore

02

Transo-Pharm USA LLC

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Transo Pharm USA Company Banner

03

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
LGM Pharma CB

04

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Metrochem

05

Inabata France S.A.S

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothIKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

Flag France
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Inabata Company Banner

06

Shandong Chenghui Shuangda Pharmac...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChina’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Shandong Chenghui Shuangda Pharmaceutical

07

Aarti Pharmalabs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WCarrow-down NDC KDMF VMF Others AUDIT arrow-down
Aarti Industries Company Banner

08

Tagoor Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Tagoor Laboratories

09

Chunghwa Chemical Synthesis & Biot...

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
CCSB Company Banner

10

Sichuan Qingmu Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothQingmu Pharma: Patients first, FDA/CEP/US-DMF/US-VMF/ASMF APIs for Humans & Vets in 100+ countries.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Company Banner
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 41012

Submission : 2024-12-31

Status : Active

Type : II

Biophore

02

RDD
Not Confirmed

03

RDD
Not Confirmed

03

RDD
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2015-11-16

Pay. Date : 2015-07-31

DMF Number : 29480

Submission : 2015-05-29

Status : Active

Type : II

blank

04

RDD
Not Confirmed

05

Cipla Ltd

India

USDMF

arrow
RDD
Not Confirmed

05

Cipla Ltd

India
arrow
RDD
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 38506

Submission : 2023-07-13

Status : Active

Type : II

blank

06

RDD
Not Confirmed

06

RDD
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2021-12-16

Pay. Date : 2021-09-29

DMF Number : 32221

Submission : 2017-11-30

Status : Active

Type : II

blank

07

RDD
Not Confirmed

08

RDD
Not Confirmed
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Granulation

read-more
read-more

Direct Compression

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Lubricants & Glidants

read-more
read-more

Co-Processed Excipients

read-more
read-more

Solubilizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Emulsifying Agents

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Coating Systems & Additives

read-more
read-more

Parenteral

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Taste Masking

read-more
read-more

API Stability Enhancers

read-more
read-more

Rheology Modifiers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions
The third quarter (Q3) of 2025 witnessed a steady rise in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA). DMFs are used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug productsA total of 323 Type II DMFs were submitted during this period, as opposed to 309 submissions in Q3 2024, marking an increase of 4.53 percent. This is the second highest number since 2018. In Q1 2025, 339 Type II filings were recorded.Across all DMF types (II, III, IV, and V), 479 DMFs were filed in Q3 2025, compared to 394 in Q3 2024, representing a 21.57 percent increase. Out of the 323 Type II DMFs submitted in Q3 2025, 40 had completed their review by the end of Q3, reflecting a processing lag between submission and review completion. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available)China maintains its lead while India posts double-digit growth in DMF submissions China and India continued to dominate DMF submissions in Q3 2025. China retained the top spot with 153 Type II DMFs, matching its submission count from Q3 2024. India recorded 131 DMFs, marking a 20.18 percent increase over 109 filings during the corresponding period last year.The United States stood a distant third with 17 filings, compared to 13 in Q3 2024. Among European nations, Italy recorded eight DMFs, doubling its 2024 tally. The Netherlands filed four, up from three. Spain submitted only one DMF, as against seven submitted in Q3 2024. Taiwan made three filings, up from one submitted in Q3 2024. Together, India, China and Taiwan accounted for about 88.9 percent of all Type II DMFs filed during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) China’s Suzhou Ryway Biotech tops corporate tally; India’s Hetero, Biophore followChina’s Suzhou Ryway Biotech led the company-wise tally with 12 DMF submissions in Q3 2025. The company had not filed any DMFs in Q3 2024.India’s Hetero Group followed with nine DMFs, maintaining the same number of filings as Q3 2024. Biophore India Pharmaceuticals ranked third with six DMFs, doubling its count from three last year.Other notable contributors include Sai Sreyas Pharmaceuticals (India) and Shanghai Haoyuan Chemexpress (China), with five DMFs each. Companies such as SNJ Group, Lunan Pharmaceutical, Allsino Pharmaceutical, Shankus Pharma, Jiangxi Xinganjiang Pharmaceutical, Sunpure Extracts, Lee Pharma, Umedica Laboratories, Linhai Tianyu Pharmaceutical and Maithri Drugs filed four DMFs each. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) Olaparib, semaglutide lead molecular filings; Dr. Reddy’s files DMF for edoxaban & tucatinibDr. Reddy’s Laboratories also featured among key DMF filers in Q3 2025, submitting two DMFs — for edoxaban tosylate monohydrate and tucatinib copovidone. Edoxaban tosylate monohydrate (marketed as Savaysa by Daiichi Sankyo) is a prescription anticoagulant used to reduce the risk of stroke and to treat deep vein thrombosis and pulmonary embolism. Patent exclusivity for Savaysa extends until October 2026 in the United States, with no generic currently available.In terms of molecules, the highest number of DMFs were filed for olaparib, semaglutide, ruxolitinib phosphate, ferric carboxymaltose, and vismodegib, with three DMFs each in Q3 2025.Olaparib, sold by AstraZeneca under the brand name Lynparza, saw DMFs being filed by BDR Lifesciences and Intas Pharmaceuticals from India, and by ScinoPharm Taiwan during the quarter.Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, continued to draw strong interest from API manufacturers. DMFs for semaglutide were filed by three Chinese companies: Yangzhou Aurisco Pharmaceutical, Zhejiang Peptites Biotech, and Fujian Genohope Biotech.Ruxolitinib phosphate, marketed by Incyte as Jakafi, saw three DMFs. Three Indian companies — Alembic Pharmaceuticals, Valary Labs, and Devi Pharmatech — filed DMFs for this API in Q3 2025. Other molecules that received multiple DMF submissions include ferric carboxymaltose (used to treat iron-deficiency anemia) and vismodegib (an oral therapy for basal-cell carcinoma). View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) First-time DMF filings span 17 companies; India leads with nine first-time DMFs The quarter saw first-time DMF filings from 17 companies. India took a lead here with nine first-time DMF filings, followed by China (six), and the US (two).The DMF filings in this quarter included inclisiran sodium (filed by Aurisco Pharmaceutical of China), pacritinib citrate (by TAPI Nl B.V. of the Netherlands), and vosoritide (by Apicore LLC of the US).Out of the 19 first-time DMFs filed in Q3 2025, four completed their Generic Drug User Fee Amendments (GDUFA) review process during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2026: The FDA Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry.Fee rates for fiscal year 2026 were published on July 30, 2025. FDA has revised fees under GDUFA III across all categories. While there is a slight increase in the DMF fee from US$ 95,084 in 2025 to US$ 102,584 in 2026, the ANDA fee has seen a sharp rise: from US$ 321,920 in 2025 to US$ 358,247 in 2026.FY 2025 and FY 2026 User Fee Rates Generic drug fee category Fees rates for FY 2025 Fees rates for FY 2026 Applications:     Abbreviated New Drug Application (ANDA) US$ 3,21,920 US$ 3,58,247 Drug Master File (DMF) US$ 95,084 US$ 1,02,584 Facilities:     Active Pharmaceutical Ingredient (API)—Domestic US$ 41,580 US$ 43,549 API—Foreign US$ 56,580 US$ 58,549 Finished Dosage Form (FDF)—Domestic US$ 2,31,952 US$ 2,38,943 FDF—Foreign US$ 2,46,952 US$ 2,53,943 Contract Manufacturing Organization (CMO)—Domestic US$ 55,668 US$ 57,346 CMO—Foreign US$ 70,668 US$ 72,346 GDUFA Program:     Large size operation generic drug applicant US$ 18,91,664 US$ 19,18,377 Medium size operation generic drug applicant US$ 7,56,666 US$ 7,67,351 Small business generic drug applicant US$ 1,89,166 US$ 1,91,838 Our viewFor several years prior to the pandemic, India had a lead in Type II DMF submissions. In recent years, China has surpassed India in DMF filings. But Q3 2025 numbers indicate that Indian drugmakers are fast catching up. Since DMFs establish trust in APIs from across the world, we feel this healthy competition between drugmakers from the two countries is good for the global pharmaceutical industry. 

Impressions: 4420

https://www.pharmacompass.com/radio-compass-blog/dmf-filings-rise-4-5-in-q3-2025-china-holds-lead-india-records-20-growth-in-submissions

#PharmaFlow by PHARMACOMPASS
13 Nov 2025

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Incyte Corporat

Ruxolitinib Phosphate

Drug Cost (USD) : 1,940,765,069

Year : 2023

Prescribers : 14041

Prescriptions : 116245

blank

02

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Incyte Corporat

Ruxolitinib Phosphate

Drug Cost (USD) : 75,729,871

Year : 2023

Prescribers : 14085

Prescriptions : 33784

blank

03

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Incyte Corporat

Ruxolitinib Phosphate

Drug Cost (USD) : 1,756,404,369

Year : 2022

Prescribers : 13486

Prescriptions : 111112

blank

04

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Incyte Corporat

Ruxolitinib Phosphate

Drug Cost (USD) : 24,255,429

Year : 2022

Prescribers : 6243

Prescriptions : 11447

blank

05

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Incyte Corporat

Ruxolitinib Phosphate

Drug Cost (USD) : 1,491,163,521

Year : 2021

Prescribers : 12664

Prescriptions : 102750

blank

06

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Incyte Corporat

Ruxolitinib Phosphate

Drug Cost (USD) : 946,803

Year : 2021

Prescribers : 382

Prescriptions : 461

blank

07

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Incyte Corporat

Ruxolitinib Phosphate

Drug Cost (USD) : 1,296,674,522

Year : 2020

Prescribers : 11361

Prescriptions : 95023

blank

08

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Incyte Corporat

Ruxolitinib Phosphate

Drug Cost (USD) : 1,125,223,954

Year : 2019

Prescribers : 10525

Prescriptions : 85335

blank

09

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Incyte Corporat

Ruxolitinib Phosphate

Drug Cost (USD) : 925,013,339

Year : 2018

Prescribers : 9163

Prescriptions : 75165

blank

10

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Incyte Corporat

Ruxolitinib Phosphate

Drug Cost (USD) : 724,218,817

Year : 2017

Prescribers : 7888

Prescriptions : 63118

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

read-more
read-more

01

Brand Name : Jakavi

Ruxolitinib

arrow
RDD
Not Confirmed

Brand Name : Jakavi

Switzerland
arrow
RDD
Not Confirmed

Ruxolitinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 1,339

2019 Revenue in Millions : 1,114

Growth (%) : 20

blank

02

Brand Name : Jakavi

Ruxolitinib

arrow
RDD
Not Confirmed

Brand Name : Jakavi

Switzerland
arrow
RDD
Not Confirmed

Ruxolitinib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 1,595

2020 Revenue in Millions : 1,339

Growth (%) : 19

blank

03

Brand Name : Jakavi

Ruxolitinib

arrow
RDD
Not Confirmed

Brand Name : Jakavi

Switzerland
arrow
RDD
Not Confirmed

Ruxolitinib

Main Therapeutic Indication : Hematology

Currency : USD

2022 Revenue in Millions : 1,561

2021 Revenue in Millions : 1,595

Growth (%) : -2

blank

04

Brand Name : Jakavi

Ruxolitinib

arrow
RDD
Not Confirmed

Brand Name : Jakavi

Switzerland
arrow
RDD
Not Confirmed

Ruxolitinib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 1,720

2022 Revenue in Millions : 1,561

Growth (%) : 10

blank

05

Brand Name : Jakavi

Ruxolitinib

arrow
RDD
Not Confirmed

Brand Name : Jakavi

Switzerland
arrow
RDD
Not Confirmed

Ruxolitinib

Main Therapeutic Indication : Oncology

Currency : USD

2024 Revenue in Millions : 1,936

2023 Revenue in Millions : 1,720

Growth (%) : 13

blank

06

Brand Name : Jakavi

Ruxolitinib

arrow
RDD
Not Confirmed

Brand Name : Jakavi

Switzerland
arrow
RDD
Not Confirmed

Ruxolitinib

Main Therapeutic Indication : Oncology

Currency : USD

2014 Revenue in Millions : 71.20%

2013 Revenue in Millions :

Growth (%) :

blank

07

Brand Name : Jakavi

Ruxolitinib

arrow
RDD
Not Confirmed

Brand Name : Jakavi

Switzerland
arrow
RDD
Not Confirmed

Ruxolitinib

Main Therapeutic Indication : Oncology

Currency : USD

2015 Revenue in Millions : 279

2014 Revenue in Millions : 410

Growth (%) : 47%

blank

08

Brand Name : Jakavi

Ruxolitinib

arrow
RDD
Not Confirmed

Brand Name : Jakavi

Switzerland
arrow
RDD
Not Confirmed

Ruxolitinib

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 581

2015 Revenue in Millions : 410

Growth (%) : 42

blank

09

Brand Name : Jakavi

Ruxolitinib

arrow
RDD
Not Confirmed

Brand Name : Jakavi

Switzerland
arrow
RDD
Not Confirmed

Ruxolitinib

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 777

2016 Revenue in Millions : 581

Growth (%) : 34

blank

10

Brand Name : Jakavi

Ruxolitinib

arrow
RDD
Not Confirmed

Brand Name : Jakavi

Switzerland
arrow
RDD
Not Confirmed

Ruxolitinib

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 977

2017 Revenue in Millions : 777

Growth (%) : 26%

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1092939-17-7 / Ruxolitinib Phosphate API manufacturers, exporters & distributors?

Ruxolitinib Phosphate manufacturers, exporters & distributors 1

98

PharmaCompass offers a list of Ruxolitinib Phosphate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ruxolitinib Phosphate manufacturer or Ruxolitinib Phosphate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ruxolitinib Phosphate manufacturer or Ruxolitinib Phosphate supplier.

API | Excipient name

Ruxolitinib Phosphate

Synonyms

1092939-17-7, Jakafi, (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate, Jakavi, Ruxolitinib (phosphate), Ruxolitinib monophosphate

Cas Number

1092939-17-7

Unique Ingredient Identifier (UNII)

436LRU32H5

About Ruxolitinib Phosphate

Ruxolitinib Phosphate is the phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.

Jakavi Manufacturers

A Jakavi manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Jakavi, including repackagers and relabelers. The FDA regulates Jakavi manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Jakavi API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Jakavi manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Jakavi Suppliers

A Jakavi supplier is an individual or a company that provides Jakavi active pharmaceutical ingredient (API) or Jakavi finished formulations upon request. The Jakavi suppliers may include Jakavi API manufacturers, exporters, distributors and traders.

click here to find a list of Jakavi suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Jakavi USDMF

A Jakavi DMF (Drug Master File) is a document detailing the whole manufacturing process of Jakavi active pharmaceutical ingredient (API) in detail. Different forms of Jakavi DMFs exist exist since differing nations have different regulations, such as Jakavi USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Jakavi DMF submitted to regulatory agencies in the US is known as a USDMF. Jakavi USDMF includes data on Jakavi's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Jakavi USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Jakavi suppliers with USDMF on PharmaCompass.

Jakavi KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Jakavi Drug Master File in Korea (Jakavi KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Jakavi. The MFDS reviews the Jakavi KDMF as part of the drug registration process and uses the information provided in the Jakavi KDMF to evaluate the safety and efficacy of the drug.

After submitting a Jakavi KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Jakavi API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Jakavi suppliers with KDMF on PharmaCompass.

Jakavi WC

A Jakavi written confirmation (Jakavi WC) is an official document issued by a regulatory agency to a Jakavi manufacturer, verifying that the manufacturing facility of a Jakavi active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Jakavi APIs or Jakavi finished pharmaceutical products to another nation, regulatory agencies frequently require a Jakavi WC (written confirmation) as part of the regulatory process.

click here to find a list of Jakavi suppliers with Written Confirmation (WC) on PharmaCompass.

Jakavi NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Jakavi as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Jakavi API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Jakavi as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Jakavi and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Jakavi NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Jakavi suppliers with NDC on PharmaCompass.

Jakavi GMP

Jakavi Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Jakavi GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Jakavi GMP manufacturer or Jakavi GMP API supplier for your needs.

Jakavi CoA

A Jakavi CoA (Certificate of Analysis) is a formal document that attests to Jakavi's compliance with Jakavi specifications and serves as a tool for batch-level quality control.

Jakavi CoA mostly includes findings from lab analyses of a specific batch. For each Jakavi CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Jakavi may be tested according to a variety of international standards, such as European Pharmacopoeia (Jakavi EP), Jakavi JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Jakavi USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty